Teva Pharmaceutical Industries (TEVA) Other financing activities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other financing activities for 18 consecutive years, with $36.0 million the latest figure, recorded in Q1 2026.

• Quarterly Other financing activities rose 1100.0% year-over-year to $36.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.0 million (up 1775.0% YoY) and the FY2025 annual result came in at $41.0 million, up 612.5% from the prior year.
• Other financing activities declined to $36.0 million in Q1 2026 per TEVA's latest filing, from $40.0 million in the prior quarter.
• Over the last five years, Other financing activities for TEVA reached as high as $40.0 million in Q4 2025 and fell as low as -$76.0 million in Q3 2023.
• A 5-year average of -$16.2 million and a median of -$4.0 million in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities sank 4100.0% — and 2026, when it jumped 1100.0%.
• Year by year, Other financing activities stood at -$3.0 million in 2022, then plunged by 2433.33% to -$76.0 million in 2023, then surged by 114.47% to $11.0 million in 2024, then soared by 263.64% to $40.0 million in 2025, then decreased by 10.0% to $36.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $36.0 million, $40.0 million, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.